Opinion

Video

Emerging Therapies: a look at the current data: PROTECT study

Key Takeaways

  • Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
  • Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
SHOW MORE

Panelists discuss how the PROTECT study’s results enhance the understanding of emerging therapies for IgA nephropathy, focusing on their potential to reduce proteinuria and modify disease progression.

  1. In the phase 3 ALIGN trial (NCT04573478), atrasentan demonstrated a 36% relative reduction in proteinuria with placebo after 36 weeks of treatment. What other data points would be relevant for clinicians?
Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD
Sobia Laique, MD | Credit: Cleveland Clinic
Sobia Laique, MD | Credit: Cleveland Clinic
What is the Global Lung Function Initiative and Its Purpose for Lung Function Testing?
© 2025 MJH Life Sciences

All rights reserved.